Open Nav

Learning from Translational Research Successes to Attract Investment

As biomedical entrepreneurs seek to apply the newest biomedical research results to invest new treatment options that might help patients, a “valley of death” in funding availability continues to endure between the academic researcher and therapies ready to begin clinical trials. Over the past decade, publicly-financed organizations designed to bridge this “valley” with development grants have created a track record with notable success stories. Such non-dilutive funding sources reduce risks during the proof-of-concept stage and make investments more attractive to equity investors. Panelists in this session will explore the characteristics of academic spinouts that continued past the grant stage to attract major and repeated investments from venture capital as well as that demonstrated therapeutic progress.

Moderator: Simone Fishburn, PhD, Editor, BioCentury and BioCentury Innovations

  • Date:Wednesday, October 17
  • Time:9:45 AM - 10:40 AM
  • Session Type:Educational Session
Speakers
Simone Fishburn
BioCentury
Alice Chen
Accelerator Life Science Partners
Kevin Grimes
Stanford University
Paul Laikind
ViaCyte
Stephanie Marrus
University of California, San Francisco (UCSF)
Shyam Patel
California Institute for Regenerative Medicine (CIRM)
Back